Kodiak Sciences KOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with ...

NY Retina, a newly launched ophthalmology practice, is set to open March 20 in a newly purchased medical office building in ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

The study titled as ‘Mitigation of Lens Opacification by a functional food in a diabetic rodent model’, published in the ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Motorists who need to wear glasses when driving could face a £1,000 fine and three points on their licence for ignoring ...

Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Hormonal changes can cause physiological and pathological changes in the eye, and eye care providers should monitor pregnant ...

Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...

Diabetes can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye ...